S&P 500   4,299.70
DOW   33,666.34
QQQ   358.01
Can Undervalued Healthcare Stocks Add Yield To Your Portfolio?
U.S. "Shadow Banks" About to Blow up again? (Ad)
Stock market today: European shares gain and Asian shares are mixed, with Chinese markets on holiday
Low Beta Stocks To Offset A Possible Hard Landing
U.S. "Shadow Banks" About to Blow up again? (Ad)
5 Cheap Ways to Ride The AI Supercycle to Profits
Nursing Home REITs: The Surprise Heroes of High Yield Investing
U.S. "Shadow Banks" About to Blow up again? (Ad)
3 Intriguing ETFs Trading Under $10 a Share
Energy Stocks Shine as High Oil Prices Boost Dividend Yields
S&P 500   4,299.70
DOW   33,666.34
QQQ   358.01
Can Undervalued Healthcare Stocks Add Yield To Your Portfolio?
U.S. "Shadow Banks" About to Blow up again? (Ad)
Stock market today: European shares gain and Asian shares are mixed, with Chinese markets on holiday
Low Beta Stocks To Offset A Possible Hard Landing
U.S. "Shadow Banks" About to Blow up again? (Ad)
5 Cheap Ways to Ride The AI Supercycle to Profits
Nursing Home REITs: The Surprise Heroes of High Yield Investing
U.S. "Shadow Banks" About to Blow up again? (Ad)
3 Intriguing ETFs Trading Under $10 a Share
Energy Stocks Shine as High Oil Prices Boost Dividend Yields
S&P 500   4,299.70
DOW   33,666.34
QQQ   358.01
Can Undervalued Healthcare Stocks Add Yield To Your Portfolio?
U.S. "Shadow Banks" About to Blow up again? (Ad)
Stock market today: European shares gain and Asian shares are mixed, with Chinese markets on holiday
Low Beta Stocks To Offset A Possible Hard Landing
U.S. "Shadow Banks" About to Blow up again? (Ad)
5 Cheap Ways to Ride The AI Supercycle to Profits
Nursing Home REITs: The Surprise Heroes of High Yield Investing
U.S. "Shadow Banks" About to Blow up again? (Ad)
3 Intriguing ETFs Trading Under $10 a Share
Energy Stocks Shine as High Oil Prices Boost Dividend Yields
S&P 500   4,299.70
DOW   33,666.34
QQQ   358.01
Can Undervalued Healthcare Stocks Add Yield To Your Portfolio?
U.S. "Shadow Banks" About to Blow up again? (Ad)
Stock market today: European shares gain and Asian shares are mixed, with Chinese markets on holiday
Low Beta Stocks To Offset A Possible Hard Landing
U.S. "Shadow Banks" About to Blow up again? (Ad)
5 Cheap Ways to Ride The AI Supercycle to Profits
Nursing Home REITs: The Surprise Heroes of High Yield Investing
U.S. "Shadow Banks" About to Blow up again? (Ad)
3 Intriguing ETFs Trading Under $10 a Share
Energy Stocks Shine as High Oil Prices Boost Dividend Yields
NASDAQ:VALN

Valneva (VALN) Stock Forecast, Price & News

$11.36
-0.25 (-2.15%)
(As of 09/28/2023 ET)
Compare
Today's Range
$11.33
$12.07
50-Day Range
$11.36
$15.29
52-Week Range
$9.07
$17.05
Volume
9,071 shs
Average Volume
5,521 shs
Market Capitalization
$789.07 million
P/E Ratio
81.14
Dividend Yield
N/A
Price Target
$22.00

Valneva MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
93.7% Upside
$22.00 Price Target
Short Interest
Healthy
0.01% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.18mentions of Valneva in the last 14 days
Based on 12 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.48) to ($0.80) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.19 out of 5 stars

Medical Sector

435th out of 969 stocks

Biological Products, Except Diagnostic Industry

65th out of 161 stocks


VALN stock logo

About Valneva (NASDAQ:VALN) Stock

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain, France.

VALN Price History

VALN Stock News Headlines

Valneva (NASDAQ:VALN) Stock Rating Reaffirmed by HC Wainwright
1907, 1929, 1998, 2007--and now 2023?
Analyst who called Lehman Bros. collapse says exact same scenario that occurred in 4 of America’s biggest economic calamities is unfolding again now. More here.
Valneva SE (NASDAQ:VALN) Q2 2023 Earnings Call Transcript
Buy Rating for Valneva: Future Prospects and Financial Analysis
1907, 1929, 1998, 2007--and now 2023?
Analyst who called Lehman Bros. collapse says exact same scenario that occurred in 4 of America’s biggest economic calamities is unfolding again now. More here.
Valneva Loss Narrows on Reduced Costs
Pfizer Lyme Disease Vaccine Shows Promise
Analyst Ratings for Valneva
See More Headlines
Receive VALN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Valneva and its competitors with MarketBeat's FREE daily newsletter.

VALN Company Calendar

Today
9/29/2023
Next Earnings (Estimated)
11/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VALN
Fax
N/A
Employees
719
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$22.00
High Stock Price Forecast
$22.00
Low Stock Price Forecast
$22.00
Forecasted Upside/Downside
+93.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-150,960,000.00
Pretax Margin
-40.08%

Debt

Sales & Book Value

Annual Sales
$380.73 million
Book Value
$3.35 per share

Miscellaneous

Free Float
59,100,000
Market Cap
$789.07 million
Optionable
Not Optionable
Beta
2.69
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Mr. Thomas Lingelbach (Age 60)
    Chairman of the Management Board, Pres & CEO
    Comp: $853.43k
  • Mr. Peter Buhler (Age 52)
    CFO & Management Board Member
    Comp: $566.26k
  • Mr. Franck Grimaud MBA (Age 56)
    Director Gen., Chief Bus. Officer & Member of Management Board
    Comp: $423.93k
  • Mr. Frederic Jacotot (Age 58)
    VP of Legal & IP, Gen. Counsel, Corp. Sec. and Member of Management Board
    Comp: $325.04k
  • Dr. Juan-Carlos Jaramillo M.D. (Age 51)
    Chief Medical Officer & Member of the Management Board
    Comp: $514.58k
  • Ms. Dipal Patel (Age 49)
    Chief Commercial Officer & Member of Management Board
    Comp: $826.98k
  • Mr. Perry Celentano
    Interim Chief Operating Officer
  • Mr. Joshua Drumm Ph.D.
    VP of Investor Relations
  • Ms. Laetitia Bachelot-Fontaine
    VP of Global Communications & European Investor Relations
  • Mr. Gerald Strohmaier
    VP of Human Resource













VALN Stock - Frequently Asked Questions

Should I buy or sell Valneva stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Valneva in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" VALN shares.
View VALN analyst ratings
or view top-rated stocks.

What is Valneva's stock price forecast for 2023?

2 brokerages have issued twelve-month price targets for Valneva's stock. Their VALN share price forecasts range from $22.00 to $22.00. On average, they predict the company's share price to reach $22.00 in the next year. This suggests a possible upside of 93.7% from the stock's current price.
View analysts price targets for VALN
or view top-rated stocks among Wall Street analysts.

How have VALN shares performed in 2023?

Valneva's stock was trading at $12.72 at the start of the year. Since then, VALN stock has decreased by 10.7% and is now trading at $11.3601.
View the best growth stocks for 2023 here
.

Are investors shorting Valneva?

Valneva saw a increase in short interest in the month of September. As of September 15th, there was short interest totaling 6,600 shares, an increase of 24.5% from the August 31st total of 5,300 shares. Based on an average trading volume of 5,100 shares, the days-to-cover ratio is presently 1.3 days. Approximately 0.0% of the shares of the company are short sold.
View Valneva's Short Interest
.

When is Valneva's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our VALN earnings forecast
.

What guidance has Valneva issued on next quarter's earnings?

Valneva issued an update on its FY 2023 earnings guidance on Thursday, September, 21st. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $239.78 million-$283.38 million, compared to the consensus revenue estimate of $180.50 million.

When did Valneva IPO?

(VALN) raised $99 million in an IPO on Thursday, May 6th 2021. The company issued 3,500,000 shares at a price of $28.24 per share. Goldman Sachs, Jefferies, Guggenheim Securities and Bryan, Garnier & Co. acted as the underwriters for the IPO.

What is Valneva's stock symbol?

Valneva trades on the NASDAQ under the ticker symbol "VALN."

How do I buy shares of Valneva?

Shares of VALN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Valneva's stock price today?

One share of VALN stock can currently be purchased for approximately $11.36.

How much money does Valneva make?

Valneva (NASDAQ:VALN) has a market capitalization of $789.07 million and generates $380.73 million in revenue each year. The company earns $-150,960,000.00 in net income (profit) each year or $0.14 on an earnings per share basis.

How many employees does Valneva have?

The company employs 719 workers across the globe.

How can I contact Valneva?

The official website for the company is valneva.com. The company can be reached via phone at 33-2-28-07-37-10 or via email at investors@valneva.com.

This page (NASDAQ:VALN) was last updated on 9/29/2023 by MarketBeat.com Staff

My Account -